Efficacy of Low Dose Sofosbuvir and Daclatasvir in Treatment of Chronic Hepatitis C in End Stage Renal Disease

Abstract

Background: Chronic hepatitis C infection is common in patients with end stage renal disease. The management of hepatitis C virus infection has been greatly influenced by the availability of direct acting antivirals. Aim: To determine the efficacy of low dose Sofosbuvir and Daclatasvir in treatment of chronic hepatitis C in patients with end stage renal disease. Study design: Descriptive case series. Place and study duration: The study was conducted in the Department of Nephrology at Shaikh Zayed Hospital, Lahore from 24th March, 2019 to 23rd September, 2019. Methodology: A total of 180 patients were enrolled in the study. Serum load of HCV was performed by PCR at baseline, and patients were started on low dose of Sofosbuvir (200mg) and Daclatasvir (60mg), once a day orally for 12 weeks and treatment efficacy was re-assessed by PCR after 12 weeks. Results: A total of 180 patients were enrolled in the study. The mean age of the patients was 40.53±11.210, mean number of dialysis sessions was 13.98±7.96. There were 59.9% males and 41.1% females. Treatment was efficacious in 91.7% of the patients. Side effects associated with treatment were fatigue (23.9%), nausea (12.8%), headache (11.7%) and anemia (5%). No effect was seen of age, gender, number of dialysis sessions and previous history of treatment on efficacy of treatment. Conclusion: Low dose Sofosbuvir and Daclatasvir were effective in the treatment of hepatitis C infection in patients with end stage renal disease and had a good safety profile. Keywords: End Stage Renal Disease, Chronic Hepatitis C, Direct Acting Antiviral Agent